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Who gets severe gynaecomastia among HIV-infected children in the UK and Ireland? 
 
UNSTRUCTURED ABSTRACT 
There are few data on gynaecomastia in HIV-infected children. Within the UK/Ireland’s national 
cohort, 56/1,873 (3%) HIV-infected children had gynaecomastia, of which 10 (0.5%) were severe.  All 
10 had received antiretroviral therapy for median 27.5 [21,42] months. 4/10 had received efavirenz, 
7/10 and 6/10 stavudine and/or didanosine respectively. Five were non-reversible, despite changing 
ART, and required breast reduction surgery.  
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Background 
Gynaecomastia has been described in HIV-infected adults taking antiretroviral therapy (ART) and has 
been linked to didanosine (ddI), efavirenz (EFV) and protease inhibitors (PI) [1-4], but very few cases 
have been described in HIV infected children [5-8].   We explored the frequency, aetiology and 
management of severe gynaecomastia in children with perinatal HIV in the UK and Ireland’s national 
Collaborative HIV Paediatric Study (CHIPS) cohort. 
 
Methods 
Details of the CHIPS cohort have been published previously [9].  Cases of gynaecomastia were 
identified from the CHIPS dataset up to April 2014, and additional case note review was undertaken 
to gather additional information.  Severity of gynaecomastia was defined as mild (minor breast 
enlargement, no skin redundancy) moderate (moderate breast enlargement, minor skin redundancy) 
or severe (in males, marked breast enlargement, major skin redundancy (resembles female breast), in 
females excessive breast hypertrophy interfering with everyday activities).  Descriptive statistics were 
calculated using Stata 13 (StataCorp, College Station, Texas). 
 
Results 
Of 1,873 children ever in CHIPS, 52% (976) were female, 77% (1,452) were black African, and the 
median age at last follow-up was 15 [interquartile range, IQR 11, 17] years.  A total of 56 (3%) had 
gynaecomastia, reported as mild (25), moderate (23) or severe (10).   Of the 10 severe cases, 9 were 
male (Table 1).   At onset the median age of severe cases was 13.5 [12, 14] years.   All were on ART, 
and had been on their current regimen for a median of 27.5 [21, 42] months and on any ART regimen 
for 60.5 [31, 88] months.   At time of report, 5 were on NNRTI-based regimens (EFV 4, nevirapine 1) 
and 5 PI-based (ritonavir-boosted lopinavir 3, nelfinavir (NVF) 2).   Current NRTI backbones included 
lamivudine (3TC) (6), abacavir (ABC) (4), stavudine (d4T) (4), ddI (6) and tenofovir (2).   All 10 had 
previous or current exposure to d4T, ddI and/or EFV (7 d4T for a median of 42 [21, 74] months, 7 ddI 
for 21 [15, 22] months, 4 EFV for 29 [19, 39] months).  9/10 young people had a body mass index <25 
(healthy/ underweight) and 6 had lipodystrophy at other sites (5/6 had exposure to d4T; ¼ to EFV).   6 
patients switched ART regimens (3 patients subsequently stopped ART) with complete resolution 
reported within 2 years.   5 patients required breast reduction surgery and 1 was considering surgery 
at time of last follow up.   One patient transferred to adult services and their outcome is unknown. 
 
Discussion 
Mild to moderate gynaecomastia was relatively common in our cohort.   Severe cases occurred in 1 in 
200 children and were more likely in males, which may reflect difficulties in distinguishing normal 
pubertal development and/or obesity from pathological breast hypertrophy in girls.  Only 2 severe 
cases occurred before age 12 years (both on stavudine and reversed with change of ART). Thus our 
findings support other reports that pre-pubertal gynaecomastia is rare, for example no cases were 
seen in the CHAPAS 3 trial in which 478 children aged under 13 years, 33% on d4T were followed for 
a median 2.3 years [10]. 3 children (aged 12, 12 and 15 years) in the ARROW trial of 1206 children 
(median age 6 [2 – 9] years, 37% on EFV; none on d4T- based ART) changed regimen due to 
lipodystrophy/gynaecomastia during 5 years of follow up [11].  
 
Within our cohort initial management of gynaecomastia varied from immediate change of ART 
regimen to differing periods of observation, most of which ended with a recommended change in ART.  
Uncertainty over the time for resolution of gynaecomastia remains and is influenced by aetiology;  
idiopathic gynecomastia in children takes 0.8 – 2.6 years to resolve [12].  In adults gynaecomastia can 
be a transient phenomenon possibly reflecting a form of immune reconstitution [4] or resolve within 
a mean of ~5 months after withdrawal of EFV [2].  In a cohort of HIV-infected adult males on a variety 
of ART combinations (55% EFV) 20/21 of those followed for over a year had spontaneous resolution 
within 17 months (mean, 8.8 months) without modification of ART [13].  Substantial resolution is 
unlikely if gynaecomastia persists for more than a year as fibrotic tissue is usually present [14].   Whilst 
rare it must be remembered that malignancy, especially lymphoma, can also present as breast 
enlargement [15]. 
 
Conclusions 
The overall prevalence of severe gynaecomastia in children and young people living with HIV was 0.5%; 
most had been exposed to ART drugs known to be associated with the condition.  Timely recognition 
of true drug-induced gynaecomastia offers the possibility of non-invasive intervention as reversibility 
is more likely if gynaecomastia has developed recently.  The higher prevalence in males and a single 
severe case in a female may reflect the difficulty in diagnosing severe gynaecomastia in peri-pubertal 
females.  Considering the devastating potential impact of this condition on adherence in perinatally 
HIV-infected adolescents, prompt identification is important.  Uncertainty remains over optimal 
management and it is critical to involve the patient in the decision making process.  In our study, 
severe cases were more likely to have a low or normal BMI; in those with a higher BMI or just starting 
treatment, adult data suggest a watch and wait approach for a period of up to 9 months may be 
appropriate.   However, where alternative treatments are available, an early switch to ART 
combinations with a more favourable metabolic profile is recommended. 
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